Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Sep 27;207(10):2195–2206. doi: 10.1084/jem.20101123

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2010 Dougan et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 6. — Systemic delivery of IAP antagonists is well tolerated and leads to T cell hyperresponsiveness. (A–D) Mice were administered 750 µg M1 daily for 1 wk by gastric lavage. Spleen cells were harvested and analyzed by flow cytometry using the indicated markers. Six animals were used per group. (A) Comparison of total CD4⁺ and CD8⁺ T cells in mice treated with M1 or control (Ctl.) compound. (B) Quantification of NK1.1/CD3 staining on spleen cells from M1-treated mice. (C, left) Flow cytometry plots showing CD69⁺CD3⁺ T cells in M1-treated and control animals. (right) Quantification of CD69/CD3 staining from the left panel. (D) 10⁵ CD4⁺ T cells were isolated from mice treated with M1 and stimulated with anti-CD3/CD28 for 48 h. Labels refer to the treatment conditions of the mouse from which T cells were isolated for analysis; IL-2 was measured by ELISA. (A–D) Error bars represent SEM. Results are representative of two independent experiments.